ArticleOpen veterinary journal2025
Effects of sildenafil and metformin on endothelin-1 in the progression of pulmonary hypertension.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary hypertension (PH) is a progressive and potentially fatal condition if left untreated. Currently, only sildenafil and bosentan have been approved by the Food and Drug Administration for the medical treatment of pediatric patients. The availability of bosentan, in a developing country, such as Indonesia, is a challenge. Aim: To evaluate the effect of sildenafil and metformin on endothelin (ET)-1 levels in the progression of PH. Methods: Forty-eight, 12-week-old, male Wistar rats, weighing 117-193 g, were injected by monocrotaline (MCT) [60 mg/kg body weight (BW)] subcutaneously. The rats were then randomly assigned to four groups (control, sildenafil, metformin, and sildenafil plus metformin). One day after MCT injection, sildenafil (5 mg/kg BW) and metformin (100 mg/kg BW) were administered once daily for 21 days. Right heart catheterization was performed on day 22 after anesthesia with ketamine 50 mg/kg BW and xylazine 5 mg/kg BW intramuscularly. Blood was taken intracardially for approximately 3.5 ml, and the rats were euthanized. The serum was stored in -20° refrigerator before ELISA analysis. The lung was harvested and paraffin-blocked for later histology analysis. Blood serum was analyzed for ET-1, and a section of paraffin-blocked lung was stained with hematoxylin-eosin and α-smooth muscle actin. Intima media thickness (IMT) of 50-200 µm artery and ratio of pulmonary artery (PA) smooth muscle cells/fibroblast were analyzed. Results: The mean PA pressure (mPAP) and ET-1 of the treatment group were significantly lower than those of the control group. IMT was significantly lower in the sildenafil plus metformin group than in the other groups. Conclusion: Sildenafil and metformin alone or in combination improve mPAP and ET-1 levels. Sildenafil plus metformin prevents artery remodeling in the PH model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.